Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNS002 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JNS002 | EXPERIMENTAL | JNS002 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle. |
| Name | Type | Description |
|---|---|---|
| JNS002 | DRUG | 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle. |
Inclusion Criteria: * Patients confirmed diagnosis of multiple myeloma with evaluable disease parameters (1.Presence of M-protein in the serum and/or urine, 2.Increased plasma cells in the bone marrow or biopsy-proven plasmacytoma, 3.Presence of related organ tissue impairment) * Patients with prog...
Top 20 of 25 competitors
JNS002 is an investigational small molecule being studied for the treatment of multiple myeloma. It is a liposomal formulation of doxorubicin hydrochloride, designed for use in patients with relapsed or refractory disease. The drug is currently in early clinical development and has not been approved by regulatory authorities.
JNS002 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research on this investigational oncology drug for multiple myeloma.
JNS002 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated in clinical trials for safety and efficacy in patients with multiple myeloma.
JNS002 has been studied in one completed Phase 1 clinical trial, identified by the National Clinical Trial number NCT01371227. This trial evaluated the drug in patients with relapsed or refractory multiple myeloma in Japan, enrolling a total of 3 participants.
Yes, JNS002 is also known as doxorubicin hydrochloride liposome injection. The clinical trial for JNS002, NCT01371227, specifically evaluated this liposomal formulation of doxorubicin in patients with relapsed or refractory multiple myeloma.